• Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) over-the-counter medicine is focused on addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). More >>

  • Anatara Investor Presentation

    Anatara Lifesciences provides an update to shareholders and investors. Commencing clinical trials from Q1 FY22, with fast potential speed to market. More>>

  • Anatara Animal Health Update

    Anatara Lifesciences provides an update on initiation of a challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf) in collaboration with the University of New England’s Poultry Hub Autralia. More >>

  • Summary of GaRP preclinical studies

    Anatara’s Gastrointestinal ReProgramming (GaRP) product successfully completes preclinical program – provides strong scientific proof that the unique over-the-counter medicine may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a specialist life sciences company with expertise in developing products for animal and human health. We are currently focused on building a pipeline of evidence-based, over-the-counter gastrointestinal health products, through in-house development and in-licencing and distribution opportunities.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Recent coverage

News

Investors

Investors Home

Pause